Together with recently published data, our work identifies the spliceosome as a potential target in cancers and suggests that tumours display different sensitivity to disruption of Prp8 function depending on the driver oncogene (Hsu et al., 2015). This evidence concerns the gene PRPF8 and neoplasm.